Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies

David W. Hoskin, Jana Stankova, Stephen K. Anderson, John C. Roder

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

11 Citas (Scopus)

Resumen

Binding of CD3-specific antibodies to the TcR-CD3 complex results in T cell activation without the need for occupation of the T cell receptor (TcR) by its ligand. Murine T cells activated in this manner will kill a broad range of tumor targets but not normal lymphoblasts. We report here that non-specific cytolytic activity can be induced in vivo by a single i.p. injection of nonlytic 145-2C11 anti-CD3 monoclonal antibody. At least three populations of effector cells are activated in these mice. These are non-MHC(major histocompatibility complex) restricted cytotoxic T lymphocytes, activated natural killer cells, and lymphokine-activated killer cells. Anti-CD3 treatment is effective in significantly reducing the number of lung tumor nodules which form in mice inoculated with oncogenic ras-transfected syngeneic 10T1/2 fibroblasts. Anti-CD3-activated killer cells may, therefore, find a future role in cancer immunotherapy.

Idioma originalEnglish
Páginas (desde-hasta)226-230
Número de páginas5
PublicaciónCancer Immunology, Immunotherapy
Volumen29
N.º3
DOI
EstadoPublished - jul. 1989

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Huella

Profundice en los temas de investigación de 'Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies'. En conjunto forman una huella única.

Citar esto